Related Experiment Video
Updated: May 27, 2025

Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease
Published on: April 17, 2017
The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular
Kim Kant-Smits1, Bart Bartels1, Laura van der Heiden2
1Ms. Kant-Smits and Drs. Bartels and Hulzebos are affiliated with Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
Abstract:
Background: Spinal muscular atrophy (SMA) is often complicated by respiratory problems. The disease-modifying therapies (DMTs) (nusinersen, onasemnogene abeparvovec, and risdiplam) have improved survival, motor function, and functional muscle strength in patients with SMA, but their effects on lung function and respiratory muscle strength need further clarification. Therefore, we performed a systematic review of studies that documented the effects of DMTs on lung function and respiratory muscle strength in patients with SMA types I, II, III, and IV. Methods: We searched the electronic databases PubMed/MEDLINE, CINAHL, Embase, and Web of Science up to December 2023. We included pre-post studies that determined the effect of DMTs for SMA on lung function or respiratory muscle strength in patients with SMA. Where possible, we performed a meta-analysis using a random-effects model with generic inverse variance weighing. Results: We included 19 studies of 376 identified records (16 longitudinal cohort studies and 3 case series) with 384 participants. Seventeen studies investigated the effect of nusinersen, and two studies investigated the effect of risdiplam. Seventeen studies had a moderate and two had a high risk of bias. Most of these studies did not report statistically significant improvement in lung function or respiratory muscle strength after treatment with nusinersen or risdiplam. A meta-analysis of 13 studies showed no statistically significant improvement in FVC after 2, 6, 10, and > 12 months of treatment with nusinersen. Conclusions: The findings of this review indicate that there is moderate evidence that nusinersen does not improve FVC, FEV1, peak expiratory flow, or maximum inspiratory pressure in subjects with SMA types I, II, III, or IV. There was no statistically significant decline in lung function and respiratory muscle strength after treatment. This may suggest that nusinersen may have stabilized lung function and respiratory muscle strength.
More Related Videos
09:37Evaluation of Respiratory Muscle Activation Using Respiratory Motor Control Assessment RMCA in Individuals with Chronic Spinal Cord Injury
Published on: July 19, 2013
09:18Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
Published on: January 12, 2019
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
COPD: Management Using Bronchodilators and Corticosteroids
Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Skeletal Muscle Relaxants: Therapeutic Uses
Lung Capacity